They're not going to give you non-public info of course.
I'm looking for a B deal announcement in the next 2 months. It would likely come with upfront and milestone $ that will fund B development through Phase 3's for all the indications included in the deal (which would likely be all of them, ABX and anti-inflammatory). That could be around $100MM total (again, depends). Would slow issuance, and flat out stop issuance if P gets a subsequent deal (K deal would happen in about 1-2 years, pill has to through at least a Phase 1 or 1B).
The market will respond positively to that, for the prospect of stopping issuance and the credibility of a BP partner.
P results likely released before a deal is finalized. Hoping to hear about that timeframe next week or the following.
News 
Market Data 
Discover 
